机构：[1]Department of Breast Surgery, Second Affiliated Hospital Zhejiang University, Zhejiang 310009 Hangzhou, China.[2]Key Laboratory of Tumour Microenvironment and Immune Therapy of Zhejiang Province, Second Affiliated Hospital Zhejiang University, Zhejiang 310009 Hangzhou, China.[3]Department of Breast Surgery, Affiliated Hangzhou First People’s Hospital Zhejiang University, Zhejiang 310006 Hangzhou, China.[4]Department of Anatomy School of Medicine, Zhejiang University, Zhejiang 310058 Hangzhou, China.[5]School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan 610064, China.[6]Department of Clinical Neuroscience Centre for Molecular Medicine, Karolinska Institute, Stockholm 17176, Sweden
Endocrine therapies with SERMs (selective estrogen receptor modulators) or SERDs (selective estrogen receptor downregulators) are standard therapies for patients with estrogen receptor (ER)-positive breast cancer. Multiple small molecule inhibitors targeting the PI3K-AKT-mTOR pathway or CDK4/6 have been developed to be used in combination with anti-estrogen drugs to overcome endocrine resistance. In addition to their direct antitumor effects, accumulating evidence has revealed the tumor immune microenvironment (TIM)-modulating effects of these therapeutic strategies, which have not been properly acknowledged previously. The immune microenvironment of breast tumors plays a crucial role in tumor development, metastasis and treatment response to endocrine therapy and immunotherapy. Therefore, in our current work, we comprehensively review the immunomodulatory effect of endocrine therapy and discuss its potential applications in combination with immune checkpoint inhibitors in breast cancer treatment.
基金：
Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LR19H160001]; Zhejiang Provincial Ministry Co-construction Plan [WKJ-ZJ-1716]; Zhejiang Public Welfare Technology Research Program [LGF18H160022]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82073151]
第一作者机构：[1]Department of Breast Surgery, Second Affiliated Hospital Zhejiang University, Zhejiang 310009 Hangzhou, China.[2]Key Laboratory of Tumour Microenvironment and Immune Therapy of Zhejiang Province, Second Affiliated Hospital Zhejiang University, Zhejiang 310009 Hangzhou, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Breast Surgery, Second Affiliated Hospital Zhejiang University, Zhejiang 310009 Hangzhou, China.[2]Key Laboratory of Tumour Microenvironment and Immune Therapy of Zhejiang Province, Second Affiliated Hospital Zhejiang University, Zhejiang 310009 Hangzhou, China.[5]School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan 610064, China.[6]Department of Clinical Neuroscience Centre for Molecular Medicine, Karolinska Institute, Stockholm 17176, Sweden
推荐引用方式(GB/T 7714)：
Huang Huanhuan,Zhou Jun,Chen Hailong,et al.The immunomodulatory effects of endocrine therapy in breast cancer[J].JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH.2021,40(1):doi:10.1186/s13046-020-01788-4.
APA：
Huang, Huanhuan,Zhou, Jun,Chen, Hailong,Li, Jiaxin,Zhang, Chao...&Ni, Chao.(2021).The immunomodulatory effects of endocrine therapy in breast cancer.JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,40,(1)
MLA：
Huang, Huanhuan,et al."The immunomodulatory effects of endocrine therapy in breast cancer".JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 40..1(2021)
医学